WILLOW BIOSCIENCES ANNOUNCES CLOSING OF PRIVATE PLACEMENT OF UNITS
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES Calgary, Alberta – July 18, 2024 –
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES ORFOR DISSEMINATION IN THE UNITED STATES Calgary, Alberta – July 18, 2024 –
Company announced multi-product development and licensing partnership with Laurus Labs for manufacturing active pharmaceutical ingredients Company anticipates revenue of over
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Sunnyvale, California – June 3, 2024
Collaboration provides Laurus access to Willow’s AI-driven bioengineering platform The strategic alliance includes an initial seven high-value advanced intermediates and
Company continues to advance its corticosteroid production platform and anticipates signing a large strategic partnership in Q2 2024 Signed two
Completed the reorganization of the Company during 2023 with all lab operations now located in the Sunnyvale, California Record revenue
Phone: +1 403 910 5140
Email: info@willowbio.com
© 2023 Willow Biosciences Inc.
Powered by BragDeal Inc.
Focused on identifying and deploying additional genetic elements and solutions to further enhance production of our yeast strains and processes. This state-of-the-art R&D facility includes high-throughput molecular biology and screening technologies, high-end analytical instrumentation and fermentation capabilities along with systems to rapidly evaluate high volumes of data and results.